<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39209740</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2397-3269</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>29</Day></PubDate></JournalIssue><Title>BMJ open ophthalmology</Title><ISOAbbreviation>BMJ Open Ophthalmol</ISOAbbreviation></Journal><ArticleTitle>Prostaglandin analogues signal detection by data mining in the FDA Adverse Event Reporting System database.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e001764</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjophth-2024-001764</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aims to identify safety signals of ophthalmic prostaglandin analogues through data mining the Food and Drug Administration Adverse Event Reporting System (FAERS) database.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A data mining search by proportional reporting ratio, reporting OR, Bayesian confidence propagation neural network, information component 0.25 and χ<sup>2</sup> for safety signals detection was conducted to the FAERS database for the following ophthalmic medications: latanoprost, travoprost, tafluprost and bimatoprost.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">12 preferred terms were statistically associated: diabetes mellitus, n=2; hypoacusis, n=2; malignant mediastinal neoplasm, n=1; blood immunoglobulin E increased, n=1; cataract, n=1; blepharospasm, n=1; full blood count abnormal, n=1; skin exfoliation, n=1; chest discomfort, n=1; and dry mouth, n=1.</AbstractText><AbstractText Label="LIMITATION OF THE STUDY" NlmCategory="UNASSIGNED">The FAERS database's limitations, such as the undetermined causality of cases, under-reporting and the lack of restriction to only health professionals reporting this type of event, could modify the statistical outcomes. These limitations are particularly relevant in the context of ophthalmic drug analysis, as they can affect the accuracy and reliability of the data, potentially leading to biased or incomplete results.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings have revealed a potential relationship due to the biological plausibility among malignant mediastinal neoplasm, full blood count abnormal, blood immunoglobulin E increased, diabetes mellitus, blepharospasm, cataracts, chest discomfort and dry mouth; therefore, it is relevant to continue investigating the possible drug-event association, whether to refute the safety signal or identify a new risk.</AbstractText><CopyrightInformation>© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Contreras-Salinas</LastName><ForeName>Homero</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-9918-2024</Identifier><AffiliationInfo><Affiliation>Pharmacovigilance Department, Laboratorios Sophia SA de CV, Zapopan, Jalisco, Mexico homero.contreras@sophia.com.mx.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romero-López</LastName><ForeName>María Soledad</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Pharmacovigilance Department, Laboratorios Sophia SA de CV, Zapopan, Jalisco, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olvera-Montaño</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Research, Laboratorios Sophia SA de CV, Zapopan, Jalisco, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodríguez-Herrera</LastName><ForeName>Lourdes Yolotzin</ForeName><Initials>LY</Initials><AffiliationInfo><Affiliation>Pharmacovigilance Department, Laboratorios Sophia SA de CV, Zapopan, Jalisco, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open Ophthalmol</MedlineTA><NlmUniqueID>101714806</NlmUniqueID><ISSNLinking>2397-3269</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011465">Prostaglandins, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009883">Ophthalmic Solutions</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="Y">Adverse Drug Reaction Reporting Systems</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057225" MajorTopicYN="Y">Data Mining</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="Y">United States Food and Drug Administration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011465" MajorTopicYN="N">Prostaglandins, Synthetic</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009883" MajorTopicYN="N">Ophthalmic Solutions</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Drugs</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Glaucoma</Keyword><Keyword MajorTopicYN="N">Medical Education</Keyword><Keyword MajorTopicYN="N">Pharmacology</Keyword></KeywordList><CoiStatement>Competing interests: Laboratorios Sophia provided support in the form of salaries for authors (HC-S, MSR-L, OOM, LYR-H), but did not have any additional role.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>29</Day><Hour>22</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39209740</ArticleId><ArticleId IdType="pmc">PMC11367404</ArticleId><ArticleId IdType="doi">10.1136/bmjophth-2024-001764</ArticleId><ArticleId IdType="pii">bmjophth-2024-001764</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lusthaus JA, Goldberg I. Emerging drugs to treat glaucoma: targeting prostaglandin F and E receptors. Expert Opin Emerg Drugs. 2016;21:117–28. doi: 10.1517/14728214.2016.1151001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14728214.2016.1151001</ArticleId><ArticleId IdType="pubmed">26854598</ArticleId></ArticleIdList></Reference><Reference><Citation>Doucette LP, Walter MA. Prostaglandins in the eye: Function, expression, and roles in glaucoma. Ophthalmic Genet. 2017;38:108–16. doi: 10.3109/13816810.2016.1164193.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/13816810.2016.1164193</ArticleId><ArticleId IdType="pubmed">27070211</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari A. In: Sweet biochemistry. Kumari A, editor. Academic Press; 2018. Chapter 16 - prostaglandin synthesis; pp. 85–7.</Citation></Reference><Reference><Citation>Holló G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf. 2007;6:45–52. doi: 10.1517/14740338.6.1.45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14740338.6.1.45</ArticleId><ArticleId IdType="pubmed">17181451</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfizer Laboratories/Food and Drug Administration  Xalatan- latanoprost.  [16-Feb-2023]. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f4e73059-5ba0-4d73-9ea1-09d8d654e844&amp;type=display Available. Accessed.</Citation></Reference><Reference><Citation>Inoue K. Managing adverse effects of glaucoma medications. Clin Ophthalmol. 2014;8:903–13. doi: 10.2147/OPTH.S44708.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OPTH.S44708</ArticleId><ArticleId IdType="pmc">PMC4025938</ArticleId><ArticleId IdType="pubmed">24872675</ArticleId></ArticleIdList></Reference><Reference><Citation>Novartis Pharmaceuticals Corporation / Food and Drug Administration  Travatan Z- travoprost.  [27-Jan-2023]. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=028455e0-ae77-4213-8819-3b58ef7d6a14&amp;type=display Available. Accessed.</Citation></Reference><Reference><Citation>Allergan Inc./  Latisse- bimatoprost.  [17-Feb-2023]. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=34f83d9d-2c64-463e-8a90-9a460fedfead&amp;type=display Available. Accessed.</Citation></Reference><Reference><Citation>Akorn / Food and Drug Administration  Zioptan- tafluprost.  [10-Feb-2023]. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a3173c26-0e19-47af-a01c-3fc06b2700d1&amp;type=display Available. Accessed.</Citation></Reference><Reference><Citation>Malikova MA. Practical applications of regulatory requirements for signal detection and communications in pharmacovigilance. Ther Adv Drug Saf. 2020;11:2042098620909614. doi: 10.1177/2042098620909614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2042098620909614</ArticleId><ArticleId IdType="pmc">PMC7160767</ArticleId><ArticleId IdType="pubmed">32313617</ArticleId></ArticleIdList></Reference><Reference><Citation>Council for International Organizations of Medical Sciences (CIOMS)  Practical aspects of signal detection in pharmacovigilance- report of CIOMS Working Group VIII. 2010. https://cioms.ch/wp-content/uploads/2018/03/WG8-Signal-Detection.pdf Available.</Citation></Reference><Reference><Citation>Uppsala Monitoring Centre  Signal detection for national pharmacovigilance centres with small data sets. 2020. http://bit.ly/SmallDataSets Available.</Citation></Reference><Reference><Citation>European Medicines Agency . Guideline on good pharmacovigilance practices (GVP) module IX – signal management. 2017. p. 25.</Citation></Reference><Reference><Citation>European Medicines Agency  Guideline on good pharmacovigilance practices (GVP) module V– risk management systems (Rev 2) 2017. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-v-risk-management-systems-rev-2_en.pdf Available.</Citation></Reference><Reference><Citation>Food and Drug Administration  Data mining at FDA -- white paper.  [16-Mar-2023]. https://www.fda.gov/science-research/data-mining/data-mining-fda-white-paper Available. Accessed.</Citation></Reference><Reference><Citation>Medical Dictionary for Regulatory Activities  Welcome to MedDRA.  [23-Jun-2022]. https://www.meddra.org/ Available. Accessed.</Citation></Reference><Reference><Citation>CIOMS Working Group Practical aspects of signal detection in pharmacovigilance. 2010.</Citation></Reference><Reference><Citation>Bate A. Bayesian confidence propagation neural network. Drug Saf. 2007;30:623–5. doi: 10.2165/00002018-200730070-00011.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00002018-200730070-00011</ArticleId><ArticleId IdType="pubmed">17604417</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauben M. Artificial Intelligence and Data Mining for the Pharmacovigilance of Drug-Drug Interactions. Clin Ther. 2023;45:117–33. doi: 10.1016/j.clinthera.2023.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2023.01.002</ArticleId><ArticleId IdType="pubmed">36732152</ArticleId></ArticleIdList></Reference><Reference><Citation>Tada K, Maruo K, Isogawa N, et al. Borrowing external information to improve Bayesian confidence propagation neural network. Eur J Clin Pharmacol. 2020;76:1311–9. doi: 10.1007/s00228-020-02909-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-020-02909-w</ArticleId><ArticleId IdType="pubmed">32488331</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Kim M, Ha J-H, et al. Signal detection of methylphenidate by comparing a spontaneous reporting database with a claims database. Regul Toxicol Pharmacol. 2011;61:154–60. doi: 10.1016/j.yrtph.2011.03.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yrtph.2011.03.015</ArticleId><ArticleId IdType="pubmed">21510997</ArticleId></ArticleIdList></Reference><Reference><Citation>Ventola CL. Big Data and Pharmacovigilance: Data Mining for Adverse Drug Events and Interactions. P T. 2018;43:340–51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5969211</ArticleId><ArticleId IdType="pubmed">29896033</ArticleId></ArticleIdList></Reference><Reference><Citation>Allaj V, Guo C, Nie D. Non-steroid anti-inflammatory drugs, prostaglandins, and cancer. Cell Biosci. 2013;3:8. doi: 10.1186/2045-3701-3-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2045-3701-3-8</ArticleId><ArticleId IdType="pmc">PMC3599181</ArticleId><ArticleId IdType="pubmed">23388178</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker OL, Dahn ML, Power Coombs MR, et al. The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential Targeting. Front Oncol. 2021;11:791696. doi: 10.3389/fonc.2021.791696.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2021.791696</ArticleId><ArticleId IdType="pmc">PMC8807694</ArticleId><ArticleId IdType="pubmed">35127497</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Dubois RN. Prostaglandins and cancer. Gut. 2006;55:115–22. doi: 10.1136/gut.2004.047100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2004.047100</ArticleId><ArticleId IdType="pmc">PMC1856377</ArticleId><ArticleId IdType="pubmed">16118353</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara-Gutiérrez Á, Baladrón V. The Role of Prostaglandins in Different Types of Cancer. Cells. 2021;10:1487. doi: 10.3390/cells10061487.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10061487</ArticleId><ArticleId IdType="pmc">PMC8231512</ArticleId><ArticleId IdType="pubmed">34199169</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupulescu A. Prostaglandins, their inhibitors and cancer. Prostaglandins Leukot Essent Fatty Acids. 1996;54:83–94. doi: 10.1016/s0952-3278(96)90064-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0952-3278(96)90064-2</ArticleId><ArticleId IdType="pubmed">8848435</ArticleId></ArticleIdList></Reference><Reference><Citation>Finetti F, Travelli C, Ercoli J, et al. Prostaglandin E2 and Cancer: Insight into Tumor Progression and Immunity. Biology (Basel) 2020;9:434. doi: 10.3390/biology9120434.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biology9120434</ArticleId><ArticleId IdType="pmc">PMC7760298</ArticleId><ArticleId IdType="pubmed">33271839</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Morris RJ, Bode AM, et al. Prostaglandin Pathways: Opportunities for Cancer Prevention and Therapy. Cancer Res. 2022;82:949–65. doi: 10.1158/0008-5472.CAN-21-2297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-21-2297</ArticleId><ArticleId IdType="pmc">PMC8930508</ArticleId><ArticleId IdType="pubmed">34949672</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie JZ, Wang M-T, Nie D. Regulations of Tumor Microenvironment by Prostaglandins. Cancers (Basel) 2023;15:3090. doi: 10.3390/cancers15123090.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers15123090</ArticleId><ArticleId IdType="pmc">PMC10296267</ArticleId><ArticleId IdType="pubmed">37370700</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Lee ES, Lee EJ, et al. Targeted eicosanoids profiling reveals a prostaglandin reprogramming in breast Cancer by microRNA-155. J Exp Clin Cancer Res. 2021;40:43. doi: 10.1186/s13046-021-01839-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13046-021-01839-4</ArticleId><ArticleId IdType="pmc">PMC7831268</ArticleId><ArticleId IdType="pubmed">33494773</ArticleId></ArticleIdList></Reference><Reference><Citation>Carini C, Hudspith BN, Brostoff J. Effect of prostaglandins and cyclic nucleotides on growth and immunoglobulin secretion of two IgE myeloma cell lines. Br J Cancer. 1981;43:257–60. doi: 10.1038/bjc.1981.42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bjc.1981.42</ArticleId><ArticleId IdType="pmc">PMC2010606</ArticleId><ArticleId IdType="pubmed">7225278</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulich TR, Dakay EB, Williams JH, et al. In vivo induction of neutrophilia, lymphopenia, and diminution of neutrophil adhesion by stable analogs of prostaglandins E1, E2, and F2 alpha. Am J Pathol. 1986;124:53–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1888171</ArticleId><ArticleId IdType="pubmed">3728647</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiser-Evans MCM, Wang X-Q, Amin J, et al. Depletion of cytosolic phospholipase A2 in bone marrow-derived macrophages protects against lung cancer progression and metastasis. Cancer Res. 2009;69:1733–8. doi: 10.1158/0008-5472.CAN-08-3766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-08-3766</ArticleId><ArticleId IdType="pmc">PMC2653105</ArticleId><ArticleId IdType="pubmed">19208832</ArticleId></ArticleIdList></Reference><Reference><Citation>Cianferoni A. Non-IgE-mediated anaphylaxis. J Allergy Clin Immunol. 2021;147:1123–31. doi: 10.1016/j.jaci.2021.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2021.02.012</ArticleId><ArticleId IdType="pubmed">33832694</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y, Zhao C, Wang W, et al. Prostaglandins E2 signal mediated by receptor subtype EP2 promotes IgE production in vivo and contributes to asthma development. Sci Rep. 2016;6:20505. doi: 10.1038/srep20505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep20505</ArticleId><ArticleId IdType="pmc">PMC4744937</ArticleId><ArticleId IdType="pubmed">26852804</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkelberg AB, Linares J, Goldraij A. Glucose metabolism in isolated uteri of immature rats. Influence of prostaglandins and nitric oxide. Reprod Nutr Dev. 2006;46:1–8. doi: 10.1051/rnd:2005057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1051/rnd:2005057</ArticleId><ArticleId IdType="pubmed">16438910</ArticleId></ArticleIdList></Reference><Reference><Citation>Truchan NA, Fenske RJ, Sandhu HK, et al. Human Islet Expression Levels of Prostaglandin E2 Synthetic Enzymes, But Not Prostaglandin EP3 Receptor, Are Positively Correlated with Markers of β-Cell Function and Mass in Nondiabetic Obesity. ACS Pharmacol Transl Sci . 2021;4:1338–48. doi: 10.1021/acsptsci.1c00045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsptsci.1c00045</ArticleId><ArticleId IdType="pmc">PMC8369690</ArticleId><ArticleId IdType="pubmed">34423270</ArticleId></ArticleIdList></Reference><Reference><Citation>Carboneau BA, Allan JA, Townsend SE, et al. Opposing effects of prostaglandin E2 receptors EP3 and EP4 on mouse and human β-cell survival and proliferation. Mol Metab. 2017;6:548–59. doi: 10.1016/j.molmet.2017.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmet.2017.04.002</ArticleId><ArticleId IdType="pmc">PMC5444094</ArticleId><ArticleId IdType="pubmed">28580285</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson RP. Prostaglandins, glucose homeostasis, and diabetes mellitus. Annu Rev Med. 1983;34:1–12. doi: 10.1146/annurev.me.34.020183.000245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.me.34.020183.000245</ArticleId><ArticleId IdType="pubmed">6344749</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimple ME, Keller MP, Rabaglia MR, et al. Prostaglandin E2 receptor, EP3, is induced in diabetic islets and negatively regulates glucose- and hormone-stimulated insulin secretion. Diabetes. 2013;62:1904–12. doi: 10.2337/db12-0769.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db12-0769</ArticleId><ArticleId IdType="pmc">PMC3661627</ArticleId><ArticleId IdType="pubmed">23349487</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng Z, Lv J, Luo Y, et al. Forkhead box O1/pancreatic and duodenal homeobox 1 intracellular translocation is regulated by c-Jun N-terminal kinase and involved in prostaglandin E2-induced pancreatic beta-cell dysfunction. Endocrinology. 2009;150:5284–93. doi: 10.1210/en.2009-0671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2009-0671</ArticleId><ArticleId IdType="pubmed">19837872</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaquist ER, Walseth TF, Nelson DM, et al. Pertussis toxin-sensitive G protein mediation of PGE2 inhibition of cAMP metabolism and phasic glucose-induced insulin secretion in HIT cells. Diabetes. 1989;38:1439–45. doi: 10.2337/diab.38.11.1439.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diab.38.11.1439</ArticleId><ArticleId IdType="pubmed">2482818</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M-L, Matsunaga H, Sugiura Y, et al. Prostaglandin in the ventromedial hypothalamus regulates peripheral glucose metabolism. Nat Commun. 2021;12:2330. doi: 10.1038/s41467-021-22431-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-22431-6</ArticleId><ArticleId IdType="pmc">PMC8058102</ArticleId><ArticleId IdType="pubmed">33879780</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuo K, Ban R, Ban M. Desensitization of the Mechanoreceptors in Müller’s Muscle Reduces the Increased Reflex Contraction of the Orbicularis Oculi Slow-Twitch Fibers in Blepharospasm. Eplasty. 2014;14:e33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4166861</ArticleId><ArticleId IdType="pubmed">25328566</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan YC, Zhou W, Chan HC. Regulation of smooth muscle contraction by the epithelium: role of prostaglandins. Physiology (Bethesda) . 2011;26:156–70. doi: 10.1152/physiol.00036.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physiol.00036.2010</ArticleId><ArticleId IdType="pubmed">21670162</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang PX, Koh VTC, Cheng JF. Periorbital muscle atrophy associated with topical bimatoprost therapy. Clin Ophthalmol. 2014;8:311–4. doi: 10.2147/OPTH.S55754.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OPTH.S55754</ArticleId><ArticleId IdType="pmc">PMC3913545</ArticleId><ArticleId IdType="pubmed">24511225</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucukevcilioglu M, Bayer A, Uysal Y, et al. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost. Clin Exp Ophthalmol. 2014;42:126–31. doi: 10.1111/ceo.12163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ceo.12163</ArticleId><ArticleId IdType="pubmed">23844550</ArticleId></ArticleIdList></Reference><Reference><Citation>Andley UP, Hebert JS, Morrison AR, et al. Modulation of lens epithelial cell proliferation by enhanced prostaglandin synthesis after UVB exposure. Invest Ophthalmol Vis Sci. 1994;35:374–81.</Citation><ArticleIdList><ArticleId IdType="pubmed">8112984</ArticleId></ArticleIdList></Reference><Reference><Citation>Goto Y, Ibaraki N, Miyake K. Human lens epithelial cell damage and stimulation of their secretion of chemical mediators by benzalkonium chloride rather than latanoprost and timolol. Arch Ophthalmol. 2003;121:835–9. doi: 10.1001/archopht.121.6.835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archopht.121.6.835</ArticleId><ArticleId IdType="pubmed">12796255</ArticleId></ArticleIdList></Reference><Reference><Citation>Reina S, Sterin-Borda L, Passafaro D, et al. Anti-M(3) muscarinic cholinergic autoantibodies from patients with primary Sjögren’s syndrome trigger production of matrix metalloproteinase-3 (MMP-3) and prostaglandin E(2) (PGE(2)) from the submandibular glands. Arch Oral Biol. 2011;56:413–20. doi: 10.1016/j.archoralbio.2010.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.archoralbio.2010.08.017</ArticleId><ArticleId IdType="pubmed">21371688</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman KE, Camden JM, Woods LT, et al. Indomethacin Treatment Post-irradiation Improves Mouse Parotid Salivary Gland Function via Modulation of Prostaglandin E2 Signaling. Front Bioeng Biotechnol. 2021;9:697671. doi: 10.3389/fbioe.2021.697671.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fbioe.2021.697671</ArticleId><ArticleId IdType="pmc">PMC8351468</ArticleId><ArticleId IdType="pubmed">34381764</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Cal C, Lomniczi A, Mohn CE, et al. Decrease in salivary secretion by radiation mediated by nitric oxide and prostaglandins. Neuroimmunomodulation. 2006;13:19–27. doi: 10.1159/000093194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000093194</ArticleId><ArticleId IdType="pubmed">16691037</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J-H. Modulating effects of prostaglandins on parasympathetic-mediated secretory activities of rat salivary glands. Prostaglandins. 1986;31:1087–97. doi: 10.1016/0090-6980(86)90212-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0090-6980(86)90212-1</ArticleId><ArticleId IdType="pubmed">3763940</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone R, Barnes PJ, Fuller RW. Contrasting effects of prostaglandins E2 and F2 alpha on sensitivity of the human cough reflex. J Appl Physiol (1985) 1992;73:649–53. doi: 10.1152/jappl.1992.73.2.649.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jappl.1992.73.2.649</ArticleId><ArticleId IdType="pubmed">1399993</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee LY, Widdicombe JG. Modulation of airway sensitivity to inhaled irritants: role of inflammatory mediators. Environ Health Perspect. 2001;109 Suppl 4:585–9. doi: 10.1289/ehp.01109s4585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1289/ehp.01109s4585</ArticleId><ArticleId IdType="pmc">PMC1240586</ArticleId><ArticleId IdType="pubmed">11544168</ArticleId></ArticleIdList></Reference><Reference><Citation>Okazaki A, Hara J, Ohkura N, et al. Role of prostaglandin E2 in bronchoconstriction-triggered cough response in guinea pigs. Pulm Pharmacol Ther. 2018;48:62–70. doi: 10.1016/j.pupt.2017.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pupt.2017.09.003</ArticleId><ArticleId IdType="pubmed">28951192</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee L-Y. Respiratory sensations evoked by activation of bronchopulmonary C-fibers. Respir Physiol Neurobiol. 2009;167:26–35. doi: 10.1016/j.resp.2008.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resp.2008.05.006</ArticleId><ArticleId IdType="pmc">PMC2759402</ArticleId><ArticleId IdType="pubmed">18586581</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilley SL, Hartney JM, Erikson CJ, et al. Receptors and pathways mediating the effects of prostaglandin E2 on airway tone. Am J Physiol Lung Cell Mol Physiol. 2003;284:L599–606. doi: 10.1152/ajplung.00324.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00324.2002</ArticleId><ArticleId IdType="pubmed">12618422</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajan MS, Syam P, Liu C. Systemic side effects of topical latanoprost. Eye (Lond) . 2003;17:442–4. doi: 10.1038/sj.eye.6700351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.eye.6700351</ArticleId><ArticleId IdType="pubmed">12724721</ArticleId></ArticleIdList></Reference><Reference><Citation>Minami T, Bakoshi S, Nakano H, et al. The effects of capsaicin cream on prostaglandin-induced allodynia. Anesth Analg. 2001;93:419–23. doi: 10.1097/00000539-200108000-00037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000539-200108000-00037</ArticleId><ArticleId IdType="pubmed">11473873</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarty L. Systemic side effects of topical prostaglandin analogues: Rare but real. Indian J Ophthalmol. 2020;68:2637–8. doi: 10.4103/ijo.IJO_2039_20.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijo.IJO_2039_20</ArticleId><ArticleId IdType="pmc">PMC7774141</ArticleId><ArticleId IdType="pubmed">33120724</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai J, Jin H, Yang R, et al. Prostaglandin F2 alpha induces cardiac myocyte hypertrophy in vitro and cardiac growth in vivo. Am J Physiol. 1996;271:H2197–208. doi: 10.1152/ajpheart.1996.271.6.H2197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.1996.271.6.H2197</ArticleId><ArticleId IdType="pubmed">8997275</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra M, Chang B, James T. Drug points. Exacerbation of angina associated with latanoprost. BMJ. 2001;323:783. doi: 10.1136/bmj.323.7316.783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.323.7316.783</ArticleId><ArticleId IdType="pmc">PMC57357</ArticleId><ArticleId IdType="pubmed">11588081</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang CH, Cho YB, Choi CH, et al. The effect of topically administered latanoprost on the cochlear blood flow and hearing. Int J Pediatr Otorhinolaryngol. 2013;77:981–5. doi: 10.1016/j.ijporl.2013.03.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijporl.2013.03.025</ArticleId><ArticleId IdType="pubmed">23611671</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi J, Liu H, Wang X. Prostaglandin E1 effects on CD62p and PAC-1 in patients with sudden sensorineural hearing loss. Thromb Res. 2020;188:31–8. doi: 10.1016/j.thromres.2020.01.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.01.023</ArticleId><ArticleId IdType="pubmed">32044505</ArticleId></ArticleIdList></Reference><Reference><Citation>Rask-Andersen H, Friberg U, Johansson M, et al. Effects of intratympanic injection of latanoprost in Meniere’s disease: a randomized, placebo-controlled, double-blind, pilot study. Otolaryngol Head Neck Surg. 2005;133:441–3. doi: 10.1016/j.otohns.2005.05.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.otohns.2005.05.043</ArticleId><ArticleId IdType="pubmed">16143197</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuller B. Role of PGE-2 and Other Inflammatory Mediators in Skin Aging and Their Inhibition by Topical Natural Anti-Inflammatories. Cosmetics. 2019;6:6. doi: 10.3390/cosmetics6010006.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cosmetics6010006</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh T, Moroi R, Aritake K, et al. Prostaglandin D2 plays an essential role in chronic allergic inflammation of the skin via CRTH2 receptor. J Immunol. 2006;177:2621–9. doi: 10.4049/jimmunol.177.4.2621.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.177.4.2621</ArticleId><ArticleId IdType="pubmed">16888024</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>